Target General Infomation
Target ID
T01851
Former ID
TTDC00148
Target Name
Integrin beta-1
Gene Name
ITGB1
Synonyms
Beta(1) integrin; CD29 antigen; Fibronectin receptor beta subunit; Integrin VLA-4 beta subunit; ITGB1
Target Type
Clinical Trial
Disease Macular degeneration [ICD9: 362.5; ICD10: H35.3]
Non-small cell lung cancer [ICD10: C33-C34]
Function
Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta- 1 and alpha-11/beta-1 are receptors for collagen, and integrins alpha- 1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence g-f-p-g-e-r in collagen.
BioChemical Class
Integrin
Target Validation
T01851
UniProt ID
Sequence
MNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPT
SARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLV
LRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDF
RIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQR
ISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQ
CHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTL
SANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISI
GDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEG
NGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRK
RDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCE
ASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDT
CTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVEN
PECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGEN
PIYKSAVTTVVNPKYEGK
Structure
1K11; 1LHA; 3G9W; 3T9K; 3VI3; 3VI4; 4DX9; 4WJK; 4WK0; 4WK2; 4WK4
Drugs and Mode of Action
Drug(s) 131I-radretumab Drug Info Phase 1/2 Non-small cell lung cancer [523256]
JSM 6427 Drug Info Phase 1 Macular degeneration [522128]
Inhibitor C(-GRGDfL-) Drug Info [529125]
MK-0668 Drug Info [530343]
SB-265123 Drug Info [525536]
Antagonist JSM 6427 Drug Info [536198], [536506], [536855]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Rap1 signaling pathway
Phagosome
PI3K-Akt signaling pathway
Axon guidance
Focal adhesion
ECM-receptor interaction
Cell adhesion molecules (CAMs)
Platelet activation
Leukocyte transendothelial migration
Regulation of actin cytoskeleton
Bacterial invasion of epithelial cells
Pathogenic Escherichia coli infection
Shigellosis
Pertussis
Leishmaniasis
Toxoplasmosis
Pathways in cancer
Proteoglycans in cancer
Small cell lung cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Integrin signalling pathway
CCKR signaling map ST
Pathway Interaction Database Signaling events mediated by PRL
RhoA signaling pathway
Beta1 integrin cell surface interactions
Integrin family cell surface interactions
Arf6 trafficking events
Reelin signaling pathway
Signaling events mediated by TCPTP
Angiopoietin receptor Tie2-mediated signaling
Alpha9 beta1 integrin signaling events
CXCR4-mediated signaling events
Plexin-D1 Signaling
Syndecan-4-mediated signaling events
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
a4b7 Integrin signaling
a6b1 and a6b4 Integrin signaling
Syndecan-2-mediated signaling events
Validated targets of C-MYC transcriptional repression
VEGFR3 signaling in lymphatic endothelium
Alpha4 beta1 integrin signaling events
Signaling events mediated by focal adhesion kinase
Reactome Elastic fibre formation
Fibronectin matrix formation
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Basigin interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Other semaphorin interactions
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
CHL1 interactions
RHO GTPases Activate Formins
Platelet Adhesion to exposed collagen
WikiPathways TGF beta Signaling Pathway
Signaling of Hepatocyte Growth Factor Receptor
Focal Adhesion
Organogenesis (Part 2 of 3)
Extracellular matrix organization
Elastic fibre formation
Nanoparticle-mediated activation of receptor signaling
JAK/STAT
Primary Focal Segmental Glomerulosclerosis FSGS
Pathogenic Escherichia coli infection
Arrhythmogenic Right Ventricular Cardiomyopathy
Neural Crest Differentiation
Semaphorin interactions
Platelet Adhesion to exposed collagen
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Cell junction organization
References
Ref 522128ClinicalTrials.gov (NCT00536016) A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD. U.S. National Institutes of Health.
Ref 523256ClinicalTrials.gov (NCT01242943) Radioimmunotherapy With 131I-L19SIP in Patients With Cancer. U.S. National Institutes of Health.
Ref 525536Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Ref 529125J Med Chem. 2007 Nov 29;50(24):5878-81. Epub 2007 Nov 1.Multiple N-methylation by a designed approach enhances receptor selectivity.
Ref 530343Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6. Epub 2009 Jul 28.Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
Ref 532756Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.
Ref 536198Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol. 2006 Jun;69(6):1820-8. Epub 2006 Mar 9.
Ref 536506Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule. Curr Eye Res. 2007 Sep;32(9):801-12.
Ref 536855An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85. Epub 2008 Sep 4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.